Safety, efficacy of vadadustat explored for CKD
FDA revives federal effort to ban menthol cigarettes
29 April 2021Low risk of infection in babies born to mothers with COVID-19
29 April 2021Safety, efficacy of vadadustat explored for CKD
(HealthDay)—Vadadustat met the noninferiority criteria for cardiovascular safety versus darbepoetin alfa among patients with dialysis-dependent chronic kidney disease (DD-CKD), but not those with non-DD-CKD (NDD-CKD), according to two studies published in the April 29 issue of the New England Journal of Medicine.
